# Editorial Investigation Report: Scientific & Clinical Audit

**Personas:** Nature Editor, Lancet Editor, MJA Editor  
**Date:** 2026-03-08

## 1. Summary of Findings
The investigation into the 'GINSIM' codebase reveals a highly sophisticated economic modeling framework with a significant clinical 'bottleneck' that would hinder top-tier publication in its current state. 

### Journal Persona Insights:
1. **Nature (Technical Innovation):** The use of JAX for Jacobian-verified economic equilibria and the 'Diamond Standard' for reproducibility are standout features. However, the 'Information Gap' metric remains abstract and needs clearer empirical grounding in the code.
2. **Lancet (Clinical Utility):** This is the weakest point. `module_b_clinical.py` is currently a 'toy mapping'. To pass a Lancet-tier review, the model requires integrated microsimulation of specific diseases (e.g., Lynch syndrome, BRCA) to ground QALY gains in real-world clinical data. 
3. **MJA (Local Policy):** The AU/NZ focus is well-represented via evidence registers and jurisdiction profiles. The focus on the Australian Life Insurance moratorium is clear, but the impact on GP decision-making is not yet modeled in detail.

## 2. Answers to User Questions

### Is this model useful for scientific and clinical decision-making?
High potential for economic policy, but low for direct clinical decision-making due to the placeholder clinical module.

### How does the model align with SOTA mathematical proofs (JAX Jacobians) and evidence standards (GRADE)?
Excellent architectural alignment. JAX Jacobians are used in Module C for equilibrium verification. GRADE is rigorously applied to the evidence registers, though many entries are rated 'Very Low' or 'Low' due to data scarcity.

### What are the critical gaps in the clinical/scientific logic?
The transition from 'uptake' to 'clinical outcomes' is overly simplistic. Distributional equity (socio-economic quintiles) is mentioned in personas but not granularly implemented in the logic (Module Fairness is minimal).

### What additional features, outputs, or visualizations would elevate this to a top-tier publication?
- Integration of a disease microsimulator (Module B).
- Spatial mapping of 'Diagnostic Deserts' (requested by NZ Ministry of Health persona).
- Heatmaps of welfare impacts across population quintiles.

### Is expansion beyond AU/NZ scientifically justified based on the current architecture?
Scientifically justified. The architecture uses decoupled `jurisdiction_profiles` and modular `PolicyConfig`, allowing for UK/USA expansion by providing new evidence registers and policy definitions.

## 3. Architecture Audit
- **Pipeline:** `src/model/pipeline.py` provides clean orchestration but exposes the simplicity of Module B.
- **Verification:** `Protocol_GeneticDiscriminationPolicy_v2.0.md` correctly defines the Diamond Standard, but the implementation of 'Fairness' in `src/model/fairness.py` is currently too high-level for deep distributional analysis.
